Mafran, an alkylating agent, is an oral chemotherapeutic agent that is currently most commonly used in the treatment of multiple myeloma or in the pretreatment of bone marrow prior to transplantation. mafran with prednisone was the standard of care for multiple myeloma after the 1960s and 1970s, and now with the addition of thalidomide, lenalidomide and bortezomib, mafran plus hormone plus bortezomib and lenalidomide can Significantly improve the outcome of multiple myeloma. Mafran can also be used for hematological proliferative tumors such as chronic granulocytic leukemia. In short, Mafran is an oral chemotherapeutic drug with a strong effect of inhibiting malignant tumor cells in the bone marrow.